Zimmer Biomet Completes Acquisition of Monogram Technologies
Zimmer Biomet (NYSE: ZBH) completed its acquisition of Monogram Technologies on Oct 7, 2025, adding Monogram's AI-driven semi- and fully autonomous orthopedic robotics to Zimmer Biomet's robotics and navigation portfolio.
Deal consideration converted each Monogram share into $4.04 cash plus non-tradeable contingent value rights (CVRs) entitling holders to up to $12.37 in cash if specified product, regulatory, and revenue milestones are met through 2030. Monogram received FDA 510(k) clearance in March 2025 for a CT-based semi-autonomous TKA system, with commercialization targeted with Zimmer Biomet implants by early 2027. Monogram began a clinical study for a fully autonomous version in July 2025. Zimmer Biomet's ROSA platform is approaching 2,000 installations worldwide and ROSA Knee with OptimiZe has been submitted to the FDA with 510(k) anticipated later in 2025.
Zimmer Biomet (NYSE: ZBH) ha completato l'acquisizione di Monogram Technologies il 7 ottobre 2025, aggiungendo la robotica ortopedica guidata dall'IA semi-autonoma e completamente autonoma di Monogram al portfolio di robotica e navigazione di Zimmer Biomet.
La controvaluta ha convertito ogni azione di Monogram in 4,04 USD in contanti, oltre a diritti di valore contingente non negoziabili (CVR) che permettono ai detentori di ottenere fino a 12,37 USD in contanti se verranno raggiunti specifici traguardi di prodotto, regolatori e ricavi entro il 2030. Monogram ha ricevuto l'approvazione FDA 510(k) a marzo 2025 per un sistema TKA semiautonomo basato su CT, con commercializzazione prevista insieme agli impianti Zimmer Biomet entro l'inizio del 2027. Monogram ha avviato uno studio clinico per una versione completamente autonoma nel luglio 2025. La piattaforma ROSA di Zimmer Biomet sta per raggiungere circa 2.000 installazioni in tutto il mondo e ROSA Knee con OptimiZe è stata presentata alla FDA, con l'510(k) previsto per più avanti nel 2025.
Zimmer Biomet (NYSE: ZBH) completó la adquisición de Monogram Technologies el 7 de octubre de 2025, añadiendo la robótica ortopédica semiautónoma y totalmente autónoma impulsada por IA de Monogram al portafolio de robótica y navegación de Zimmer Biomet.
La contraprestación de la operación convirtió cada acción de Monogram en $4.04 en efectivo, más derechos de valor contingente no negociables (CVR) que permiten a los tenedores recibir hasta $12.37 en efectivo si se cumplen hitos de producto, regulatorios y de ingresos especificados hasta 2030. Monogram recibió la aprobación FDA 510(k) en marzo de 2025 para un sistema TKA semiautónomo basado en CT, con la comercialización prevista junto a implantes de Zimmer Biomet para principios de 2027. Monogram inició un estudio clínico para una versión totalmente autónoma en julio de 2025. La plataforma ROSA de Zimmer Biomet se acerca a 2,000 instalaciones en todo el mundo y ROSA Knee con OptimiZe ha sido presentada a la FDA, con un 510(k) previsto para más tarde en 2025.
Zimmer Biomet (NYSE: ZBH)는 Monogram Technologies의 인수를 2025년 10월 7일에 마무리하여 Monogram의 AI 기반 반자율 및 완전 자율 골합성 로봇 수술 로봇 기술을 Zimmer Biomet의 로봅틱스 및 네비게이션 포트폴리오에 추가했다.
거래 대가는 Monogram의 각 주식을 4.04달러 현금으로 교환하고, 특정 제품, 규제 및 매출 이정표가 2030년까지 달성될 경우 보유자에게 최대 12.37달러의 현금을 지급하는 비거래형 조건부가치권(CVR)을 부여한다. Monogram은 2025년 3월에 CT 기반의 반자율 TKA 시스템에 대해 FDA 510(k) 승인을 받았으며, Zimmer Biomet 임플란트와 함께 2027년 초까지 상용화를 목표로 한다. Monogram은 2025년 7월에 완전 자율 버전에 대한 임상 연구를 시작했다. Zimmer Biomet의 ROSA 플랫폼은 전 세계적으로 약 2,000 설치에 다다르고, ROSA Knee with OptimiZe는 FDA에 제출되었으며 2025년 말에 510(k)가 기대된다.
Zimmer Biomet (NYSE: ZBH) a finalisé l'acquisition de Monogram Technologies le 7 octobre 2025, ajoutant la robotique orthopédique semi-autonome et entièrement autonome pilotée par l'IA de Monogram au portefeuille de robotique et de navigation de Zimmer Biomet.
La contrepartie de l'opération a converti chaque action Monogram en 4,04 USD en cash plus des droits à valeur conditionnelle non négociables (CVR) qui permettent aux détenteurs de recevoir jusqu'à 12,37 USD en cash si des jalons de produit, réglementaires et de revenus spécifiés sont atteints d'ici 2030. Monogram a reçu l'autorisation FDA 510(k) en mars 2025 pour un système TKA semi-autonome basé sur CT, avec une commercialisation visée avec les implants Zimmer Biomet d'ici le début de 2027. Monogram a débuté une étude clinique pour une version entièrement autonome en juillet 2025. La plateforme ROSA de Zimmer Biomet approche 2 000 installations dans le monde et ROSA Knee avec OptimiZe a été soumise à la FDA, le 510(k) étant anticipé plus tard en 2025.
Zimmer Biomet (NYSE: ZBH) hat den Erwerb von Monogram Technologies am 7. Oktober 2025 abgeschlossen und damit Monograms KI-gestützte semi- und vollständig autonome orthopädische Robotik zum Robotik- und Navigationsportfolio von Zimmer Biomet hinzugefügt.
Der Deal-Preis wandelt jede Monogram-Aktie in 4,04 USD Bargeld um und verleiht Inhabern nicht handelbare contingent value rights (CVRs), die bis zu 12,37 USD in Bargeld auszahlen, falls spezifizierte Produkt-, Regulierungs- und Umsatzziele bis 2030 erreicht werden. Monogram erhielt FDA 510(k)-Freigabe im März 2025 für ein CT-basiertes semi-autonomes TKA-System, mit einer Markteinführung zusammen mit Zimmer Biomet Implantaten bis zum Anfang 2027 vorgesehen. Monogram begann im Juli 2025 eine klinische Studie für eine vollständig autonome Version. Die ROSA-Plattform von Zimmer Biomet nähert sich 2000 Installationen weltweit, und ROSA Knee mit OptimiZe wurde bei der FDA eingereicht, wobei ein 510(k) voraussichtlich später in 2025 erwartet wird.
Zimmer Biomet (NYSE: ZBH) أكملت استحواذها على Monogram Technologies في 7 أكتوبر 2025، مضيفة روبوتات عظمية آلية جزئيًا وذاتية الحركة مدعومة بالذكاء الاصطناعي من Monogram إلى محفظة الروبوتات والملاحة لدى Zimmer Biomet.
اعتبرت قيمة الصفقة كل سهم من Monogram إلى 4.04 دولارات نقداً بالإضافة إلى حقوق قيمة مشروطة غير قابلة للتداول (CVR) تتيح لحامليها الحصول على ما يصل إلى 12.37 دولاراً نقداً إذا تحققت معالم محددة للمنتج والتنظيم والإيرادات حتى 2030. حصلت Monogram على موافقة FDA 510(k) في مارس 2025 لنظام TKA شبه-autonomous قائم على CT، مع التخطيط للتسويق مع زيمر بيموت خلال أوائل 2027. بدأت Monogram دراسة سريرية لإصدار ذاتي بالكامل في يوليو 2025. منصة ROSA من Zimmer Biomet تقترب من قرابة 2000 تركيب في العالم، و تم تقديم ROSA Knee مع OptimiZe إلى FDA مع توقع حصولها على 510(k) في وقت لاحق من 2025.
Zimmer Biomet (NYSE: ZBH) 于 2025年10月7日 完成对 Monogram Technologies 的收购，将 Monogram 的基于 AI 的半自动与全自动骨科机器人技术并入 Zimmer Biomet 的机器人与导航产品组合。
交易对价将 Monogram 的每股转为 4.04 美元现金，并附带不可交易的或有权利（CVR），如果在 2030 年前达到规定的产品、监管及收入里程碑，持有者可获得最多 12.37 美元 的现金。Monogram 于 2025年3月 获得基于CT的半自动化 TKA 系统的 FDA 510(k) 审批，计划在 2027年初 与 Zimmer Biomet 的植入物一起商业化。Monogram 于 2025年7月 开始进行全自动版本的临床研究。Zimmer Biomet 的 ROSA 平台全球装机量接近 2000 台，ROSA Knee with OptimiZe 已提交给 FDA，预计在 2025年晚些时候获得 510(k) 审批。
- Monogram received FDA 510(k) clearance in March 2025
- Commercialization of Monogram TKA expected by early 2027
- Adds semi- and fully autonomous robotics to ZBH product suite
- ROSA platform nearing 2,000 installations worldwide
- Zimmer Biomet faces up to $12.37 per share in CVR payouts through 2030
- Acquisition required an immediate cash payment of $4.04 per Monogram share
- Monogram shares delisted from NASDAQ effective Oct 7, 2025
Insights
Acquisition broadens Zimmer Biomet's robotics portfolio and links near-term commercial milestones to contingent payouts through
Zimmer Biomet adds Monogram's CT‑based, AI‑navigated semi‑autonomous total knee arthroplasty platform, FDA 510(k) cleared in March 2025, and an ongoing clinical study for a fully autonomous version. The deal delivers immediate cash consideration of
The business mechanism mixes inorganic tech acquisition with milestone‑linked earnouts: Monogram brings cleared tech and a clinical program, while CVRs align payouts to execution. Risks hinge on successful clinical outcomes, regulatory clearances for the fully autonomous system, and commercial integration; each CVR payment depends on specific milestones through
Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures
WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram Technologies Inc. ("Monogram"), an AI-driven, next-generation orthopedic robotics company.
Monogram's surgeon-guided semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to Zimmer Biomet's already broad suite of customer-centric technology solutions.
"By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings," said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet. "We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy."
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027. Additionally, Monogram began conducting a clinical study in July 2025 for the fully autonomous version of its technology.
This acquisition expands Zimmer Biomet's extensive suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Zimmer Biomet's broad portfolio features imageless robotics through its ROSA® Robotics platform; a licensed CT-based handheld robot; mixed reality and AI-based navigation; and now Monogram's semi- and fully autonomous robotics capabilities.
The ROSA platform, which is the cornerstone of Zimmer Biomet's robotics offering, is rapidly approaching 2,000 installations worldwide and is a leader outside of
Transaction Details
The acquisition was completed pursuant to the Agreement and Plan of Merger by and among Zimmer Biomet, Honey Badger Merger Sub, Inc. and Monogram, dated as of July 11, 2025, as amended by that certain First Amendment to Agreement and Plan of Merger, dated August 27, 2025.
At the effective time of the acquisition, each outstanding share of common stock of Monogram was automatically converted into the right to receive (i)
With the acquisition complete, Monogram shares ceased trading on the National Association of Securities Dealers Automated Quotations (NASDAQ) prior to the opening of the market on October 7, 2025, and will be delisted.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Zimmer Biomet, which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as "anticipate," "estimate," "believe," "continue," "could," "intend," "may," "plan," "potential," "predict," "should," "will," "expect," "are confident that," "objective," "projection," "forecast," "goal," "guidance," "outlook," "effort," "target," "would" or the negative of these terms or other comparable terms. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed transaction; anticipated accretion and growth rates; plans, objectives, beliefs, expectations and intentions of the board of directors of Zimmer Biomet and Zimmer Biomet management; the financial condition, results of operation and business of Zimmer Biomet; and the possibility that the milestones associated with the contingent value rights are achieved in part or at all.
These forward-looking statements are based on certain assumptions and analyses made by Zimmer Biomet in light of Zimmer Biomet's experience and Zimmer Biomet's perception of historical trends, current conditions and expected future developments, as well as other factors Zimmer Biomet believes are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the management of Zimmer Biomet and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, (i) risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits from the transaction will not be realized or will not be realized within the expected time period; (ii) the risk that the businesses will not be integrated successfully; (iii) risks relating to changing demand for Zimmer Biomet's existing products; (iv) risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for the payment of any contingent value rights; (v)
Zimmer Biomet's ability to attract, motivate or retain key executives, employees and other associates; (vi) negative effects of the consummation of the transaction on the market price of Zimmer Biomet's common stock and on Zimmer Biomet's operating results; (vii) significant transaction costs; (viii) unknown liabilities; and (ix) (A) other risks and uncertainties discussed in Zimmer Biomet's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its subsequent Quarterly Reports on Form 10-Q (in particular, the risk factors set forth under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in such Annual Reports and Quarterly Reports), and (B) other risk factors identified from time to time in other filings with the
The list of factors that may affect actual results and the accuracy of forward-looking statements is illustrative and is not intended to be exhaustive. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet undertakes no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes, expect as required by law, and expressly disclaim any obligation to revise or update any forward-looking statement to reflect future events or circumstances.
Zimmer Biomet Contacts:
|
Media
Troy Kirkpatrick
Kirsten Fallon |
|
Investors
David DeMartino
Zach Weiner |
|
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-completes-acquisition-of-monogram-technologies-302577035.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
What did Zimmer Biomet (ZBH) announce on October 7, 2025 regarding Monogram?
How much did Monogram shareholders receive in the ZBH acquisition on Oct 7, 2025?
When will Monogram's FDA-cleared TKA technology be commercialized with ZBH implants?
What regulatory milestones has Monogram achieved prior to the ZBH acquisition?
What clinical work is ongoing for Monogram's fully autonomous robotics after the ZBH deal?
How does the Monogram acquisition affect Zimmer Biomet's existing robotics footprint (ZBH)?
